Editor's note

Originally published June 2019. VLA15 subsequently entered Phase 3 as a Pfizer/Valneva collaboration and received FDA approval in May 2023 as Vaxneuvance. For current commercial intelligence on the Lyme vaccine market, see VAMV024 - Lyme Borreliosis Vaccines Forecast (2020).

The Disease Landscape

Lyme borreliosis is caused by the spirochaete bacteria Borrelia burgdorferi (predominantly North America) and Borrelia afzelii and B. garinii (predominant in Europe), transmitted via the bite of infected Ixodes ticks. Clinical presentation ranges from a characteristic expanding rash (erythema migrans, seen in approximately 70-80% of cases) through to multi-system complications including Lyme carditis, neuroborreliosis, and Lyme arthritis if untreated.

Incidence data are substantially affected by under-reporting. The US CDC estimates approximately 300,000 cases annually - roughly ten times the formally reported count. EU estimates similarly suggest 100,000-300,000 cases annually across endemic member states, with Germany, France, the UK, Sweden, and the Baltic states carrying the highest burdens. The 21st Century Cures Act established a federal advisory committee specifically for tick-borne disease, signalling political recognition of the scale of the problem.

Annual Lyme disease incidence · US + EU
~300k

Estimated annual Lyme borreliosis cases in each of the US (CDC) and EU - both substantially underestimated due to inconsistent surveillance. Combined burden represents a large addressable vaccination population.

The Shadow of LYMErix

SmithKline Beecham's LYMErix was approved by the FDA in December 1998 based on Phase 3 data showing approximately 76-92% efficacy in seropositive adults. It was commercially available for four years before withdrawal in February 2002, following sustained - and scientifically unjustified - claims that the vaccine caused autoimmune arthritis. Post-market studies and an FDA advisory committee found no such association. The withdrawal left a market gap that no manufacturer filled for nearly two decades. Baxter International and Sanofi Pasteur both initiated development programmes subsequently halted. The industry's lesson: Lyme vaccine development was unacceptably exposed to organised anti-vaccine sentiment.

Valneva VLA15: A Second Attempt

Valneva's VLA15 is a multivalent recombinant OspA-based vaccine covering six Borrelia serotypes, designed to address the antigenic diversity that made earlier single-valent approaches less effective in Europe. Phase 2 data presented in 2018 demonstrated acceptable safety and immunogenicity across age groups including children aged 5 and above. The Phase 3 programme was anticipated to begin in 2020, targeting adult and paediatric populations in North American and European endemic areas.

The commercial rationale rests on three factors: the absence of any competing licensed product, a demonstrably large and measurable disease burden, and an improved payer and regulatory environment driven by the Cures Act and rising public awareness of tick range expansion due to climate change. VacZine Analytics modelled the commercial opportunity in VAMV024 - Lyme Borreliosis Vaccines Forecast across 27 Western markets to 2040.

"LYMErix's withdrawal was a commercial failure driven by disinformation, not by science. Valneva's VLA15 represents the industry taking the rational long view - and VacZine Analytics expects it to be rewarded for that bravery."